| Literature DB >> 28291817 |
Renata Kolasa-Trela1, Malgorzata Konieczynska1, Marta Bazanek1, Anetta Undas2.
Abstract
BACKGROUND: We evaluated exercise-induced changes in the profile of circulating cytokines and growth factors in patients with AS.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28291817 PMCID: PMC5349660 DOI: 10.1371/journal.pone.0173787
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics.
| Variables | AS patients (n = 32) | Controls (n = 32) | p |
|---|---|---|---|
| Males, n (%) | 15 (46.8) | 17 (53.1) | 0.62 |
| Age (years) | 64 (23–82) | 63.5 (33–83) | 0.81 |
| BMI (kg/m2) | 30 (21–37) | 28 (21–39) | 0.19 |
| Current Smoking, n (%) | 2 (6.2) | 2 (6.2) | 1.0 |
| Hypertension, n (%) | 26 (81.2) | 27 (84.3) | 0.74 |
| Diabetes, n (%) | 7 (21.8) | 4 (12.5) | 0.32 |
| Hypercholesterolaemia, n (%) | 12 (37.5) | 2 (6.2) | 0.02 |
| Fibrinogen (g/L) | 3.26 ± 0.7 | 3.04 ± 0.5 | 0.21 |
| Total cholesterol (mM) | 5.03 ± 1.04 | 5.26 ± 1.2 | 0.41 |
| LDL cholesterol (mM) | 3.04 ± 0.8 | 3.33 ± 1.0 | 0.24 |
| HDL cholesterol (mM) | 1.48 ± 0.3 | 1.48 ± 0.4 | 0.92 |
| Triglycerides (mM) | 1.15 (0.4–4.2) | 1.15 (0.4–2.3) | 0.50 |
| Glucose (mM) | 5.85 ± 1.1 | 5.38 ± 0.5 | 0.30 |
| Creatinine (μM) | 73.8 ± 12.4 | 77.3 ± 13.9 | 0.28 |
| C-reactive protein (mg/L) | 1.23 (0.3–10.4) | 1.6 (0.2–8.0) | 0.61 |
| Aspirin, n (%) | 18 (56.2) | 10 (31.2) | 0.044 |
| Statins, n (%) | 23 (71.8) | 20 (62.5) | 0.42 |
| β-blockers, n (%) | 19 (59.3) | 12 (37.5) | 0.08 |
| ACEI, n (%) | 12 (37.5) | 15 (46.8) | 0.45 |
Data are median (interquartile range) or mean ± SD, unless otherwise stated. P value was measured using Student t-test when variables were normally distributed or by the Mann-Whitney U-test for non-normally distributed variables. Abbreviations: BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ACEI, angiotensin-converting enzyme inhibitor
Clinical, exercise and echocardiographic data.
| Variables | AS (n = 32) | K (n = 32) | p |
|---|---|---|---|
| Heart rate (bpm) | 65.3 ± 10.1 | 68.1 ± 10.9 | 0.423 |
| Systolic arterial pressure (mm Hg) | 131.9 ± 10.1 | 133.6 ± 11.9 | 0.870 |
| Diastolic arterial pressure (mm Hg) | 76.8 ± 8.8 | 78.6 ± 6.9 | 0.549 |
| Maximal workload (WATT) | 81.3 ± 21.1 | 100.8 ± 22.4 | 0.002 |
| Duration (min) | 9.0 ± 1.9 | 10.8 ± 2.7 | 0.008 |
| Heart rate (bpm) | 113.3 ± 21.9 | 122.7 ± 17.4 | 0.043 |
| Systolic arterial pressure (mm Hg) | 158.4 ± 10.2 | 166.5 ± 18.3 | 0.108 |
| Diastolic arterial pressure (mm Hg) | 83.1 ± 5.6 | 84.9 ± 9.1 | 0.257 |
| LVEF (%) | 66.3 ± 7.3 | 69.8 ± 7.6 | 0.079 |
| LVEDV (ml) | 96.4 ± 27.7 | 92.7 ± 28.3 | 0.519 |
| LVEDV/BSA (ml/m2) | 51.9 ± 13.4 | 49.2 ± 13.7 | 0.376 |
| LV mass (g) | 208.8 ± 59.6 | 150.7 ± 43.1 | <0.001 |
| LV mass BSA (g/m2) | 109.5 ± 24.0 | 78.4 ± 20.1 | <0.001 |
| LA area (cm2) | 20.3 ± 4.7 | 15.5 ± 2.9 | <0.001 |
| LA volume (ml) | 58.5 ± 23.1 | 40.5 ± 11.5 | <0.001 |
| LA volume//BSA (ml/m2) | 29.9 (17.6–65) | 22.5 (8.3–35) | <0.001 |
| Ascending aorta (mm) | 38.7 ± 5.7 | 32.8 ± 3.9 | <0.001 |
| PPG (mmHg) | 59.4 ± 19.8 | 8.0 ± 3.6 | <0.001 |
| MPG (mmHg) | 35.4 ± 14.1 | 4.4 ± 1.8 | <0.001 |
| AVA (cm2) | 1.0 ± 0.23 | ||
| AVA/BSA (cm2/m2) | 0.58 ± 0.11 | ||
| PPG (mmHg) | 75.3 ± 26.1 | ||
| MPG (mmHg) | 45.3 ± 15.9 | ||
| AVA (cm2) | 1.1 ± 0.3 | ||
| AVA/BSA (cm2/m2) | 0.58 ± 0.14 | ||
Abbreviations: LVEF- left ventricular ejection fraction; LVEDV- left ventricular end diastolic volume; BSA- body surface area; LV- left ventricle; LA- left atrium; PPG- peak pressure gradient; MPG- mean pressure gradient; AVA- aortic valve area
Fig 1Exercise-induces changes during symptom-limited exercise on a bicycle ergometer in 32 asymptomatic aortic valve stenosis patients (AS) and 32 well-matched Controls (C) in Interleukin- 6 (IL-6).
Fig 2Exercise-induces changes during symptom-limited exercise on a bicycle ergometer in 32 asymptomatic aortic valve stenosis patients (AS) and 32 well-matched Controls (C) in Interleukin- 10 (IL-10).
Fig 3Exercise-induces changes during symptom-limited exercise on a bicycle ergometer in 32 asymptomatic aortic valve stenosis patients (AS) and 32 well-matched Controls (C) in TGF-β (transforming growth factor).
Fig 4Exercise-induces changes during symptom-limited exercise on a bicycle ergometer in 32 asymptomatic aortic valve stenosis patients (AS) and 32 well-matched Controls (C) in HGF (hepatocyte growth factor).
Fig 5Exercise-induces changes during symptom-limited exercise on a bicycle ergometer in 32 asymptomatic aortic valve stenosis patients (AS) and 32 well-matched Controls (C) in VEGF (vascular endothelial growth factor).